Anne McDonald Pritchett, PhD(@pritchettpolicy):@RxPricing @axios If we want more affordable alternatives, we should start by addressing PBMs and middlemen that leave patients paying more at the pharmacy counter. We also need to look at how IRA & MFN price controls could be harming incentives for biosimilar investments.

Anne McDonald Pritchett, PhD

@pritchettpolicy

Founder, Pritchett Policy Associates Senior Associate, Center for Strategic & International Studies Innovation policies, biopharma supply chain, US leadership

加入 February 2025

218 正在關注 55 粉絲

Anne McDonald Pritchett, PhD@pritchettpolicy

2026.10.06 13:24

@RxPricing @axios If we want more affordable alternatives, we should start by addressing PBMs and middlemen that leave patients paying more at the pharmacy counter. We also need to look at how IRA & MFN price controls could be harming incentives for biosimilar investments.